BRIEF: Legend Biotech’s revenue rises 36% in second quarter
Drug maker Legend Biotech Corp. (LEGN.US) on Monday reported strong revenue growth in the second quarter of 2025 as its core cancer drug gained traction. But its net loss also…
BRIEF: Hutchmed’s revenue falls in first half of 2025
Drug maker Hutchmed (China) Ltd. (HCM.US; 0013.HK) reported its revenue fell in the first half of 2025, as a small gain for its best-selling drug failed to offset declines for…
BRIEF: Bayzed Health jumps in Hong Kong trading debut
Shares of cancer hospital operator Bayzed Health Group Inc. (2609.HK) jumped in their Hong Kong trading debut on Monday, as the company raised HK$562 million ($72 million) in an IPO that received…
Kintor Pharma shifts from cancer drugs to cosmetics as funds run low
The cash-strapped biotech has begun generating its first revenue from over-the-counter cosmetic treatments, as it pivots away from its original oncology drugs Key Takeaways: Kintor Pharma is shifting from its…
Everest Medicines drives growth with AI-powered mRNA pipeline
The company said the U.S. FDA has cleared the IND application for its self-developed EVM14, a tumor-associated antigen vaccine Key Takeaways: The FDA has cleared Everest Medicine’s EVM14 cancer vaccine…
BRIEF: Burning Rock returns to revenue growth as loss narrows
Cancer screening company Burning Rock Biotech Ltd. (BNR.US) on Wednesday reported its revenue rose 0.8% in the third quarter year-on-year to 128.6 million yuan ($17.6 million), as it returned to…
Cash-strapped Mirxes looks for lifeline in blood-based cancer detection
The Singaporean company has filed for a Hong Kong IPO, hoping to wow investors with its product that can screen for gastric cancer using blood tests Key Takeaways: Mirex’s blood-based…
